Smitha Thungathurthi, Orsu Prabhakar
India stands on the top position in the incidences of new cases of drug sensitive and resistant tuberculosis. Treatment for any ailment contemplates drug safety and patient benefits. Prolongation in QT interval is considered as one of the potential adverse effects with anti-tubercular drugs. Being asymptomatic, it is considered as one of the endpoints for cardiac safety in pharmacovigilance where it sometimes may lead to syncope and sudden cardiac death in an hour reported in few cases. The prolongation in QT interval appears to be overlooked in clinical practice which is of the major concern to look into. Generally, the treatment in multidrug resistant tuberculosis (MDRTB) includes at least one QT interval prolonging drug in the regimen. This review helps in identifying the extent of QT interval prolongation with multi drug resistant tuberculosis regimens. Manuscripts determining the antitubercular drugs involved in QT interval lengthening and few describing the health factors for the same taken into consideration in this review. QT interval prolongation ascertained with the antitubercular drugs such as levofloxacin, moxifloxacin, clofazimine, bedaquiline and delaminid along with these agents confounding factors also play a key role. Hence, predictive analyses in developing clinical decision tools are essential for health professionals. Priority to enhance for providing interventions based on evidence management in reducing the QT interval prolongation is a prerequisite. Keywords: Multi-drug resistant tuberculosis, QT interval, Electrocardiogram, QT interval prolonging drugs, risk factors.